M
M. Neil Reaume
Researcher at Ottawa Hospital
Publications - 54
Citations - 1999
M. Neil Reaume is an academic researcher from Ottawa Hospital. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 13, co-authored 42 publications receiving 1250 citations. Previous affiliations of M. Neil Reaume include Ottawa Hospital Research Institute & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis,Andrew J. Martin,Martin R. Stockler,Stephen Begbie,Kim N. Chi,Simon Chowdhury,Xanthi Coskinas,Mark Frydenberg,Wendy Hague,Lisa G. Horvath,Lisa G. Horvath,Anthony M. Joshua,Anthony M. Joshua,Nicola Jane Lawrence,Gavin Marx,Gavin Marx,John McCaffrey,Ray McDermott,Margaret McJannett,Scott North,Francis Parnis,Wendy R. Parulekar,David Pook,M. Neil Reaume,M. Neil Reaume,Shahneen Sandhu,Alvin Tan,T. Hsiang Tan,Alastair Thomson,Emily Tu,Francisco E. Vera-Badillo,Scott Williams,Sonia Yip,Alison Yan Zhang,Robert Zielinski,Christopher Sweeney +35 more
TL;DR: Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression.
Journal ArticleDOI
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli,Brenda R. Hemmelgarn,Tony Reiman,Braden J. Manns,M. Neil Reaume,Anita Lloyd,Natasha Wiebe,Scott Klarenbach +7 more
TL;DR: Use of erythropoiesis-stimulating agents in patients with cancer-related anemia improved some disease-specific measures of quality of life and decreased the use of blood transfusions, however, it increased the risk of death and serious adverse events.
Journal ArticleDOI
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
Yoo-Joung Ko,Christine M Canil,Som D. Mukherjee,Eric Winquist,Christine Elser,Andrea Eisen,M. Neil Reaume,Liying Zhang,Srikala S. Sridhar +8 more
TL;DR: Nab-paclitaxel was well tolerated in this population of patients with pretreated advanced urothelial cancer with an encouraging tumour response, and these results warrant further study of nab-pac Litaxel in second-line treatment of urothalial cancer.
Journal ArticleDOI
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).
Howard M. Sandler,Chen Hu,Seth A. Rosenthal,Oliver Sartor,Leonard G. Gomella,Mahul B. Amin,James A. Purdy,Jeff M. Michalski,Mark Garzotto,Nadeem Pervez,Alexander Balogh,George Rodrigues,Luis Souhami,M. Neil Reaume,Scott Williams,Raquibul Hannan,Eric M. Horwitz,Adam Raben,Rebecca Paulus,William U. Shipley +19 more
TL;DR: For high-risk, localized PCa, adjuvant CT improved the OS from 89% to 93% at 4 years, and additional follow-up is warranted to determine the long-term benefit of CT to the current standard of care of long- term AS+RT.
Journal ArticleDOI
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal,Chen Hu,Oliver Sartor,Leonard G. Gomella,Mahul B. Amin,James A. Purdy,Jeff M. Michalski,Mark Garzotto,Nadeem Pervez,Alexander Balogh,George Rodrigues,Luis Souhami,M. Neil Reaume,Scott Williams,Raquibul Hannan,Eric M. Horwitz,Adam Raben,Christopher A. Peters,Felix Y. Feng,William U. Shipley,Howard M. Sandler +20 more
TL;DR: For patients with high-risk nonmetastatic prostate cancer, CT with docetaxel improved OS from 89% to 93% at 4 years, with improved disease-free survival and reduction in the rate of distant metastasis.